A BamHI 3.7-kilobase (kb) fragment detected by an HLA-DQ (-chain complementary DNA (cDNA) probe and negatively associated with insulin-dependent diabetes mellitus (IDDM) was cloned and sequenced to localize the polymorphism to BamHI sites in intervening sequences of an HLA-DQ $-chain gene. A probe of the first intervening sequence (IVS 1) showed the BamHI 3.7-kb fragment in 6 of 17 HLA-DR3/4 controls but in 0 of 13 DR-identical IDDM patients. All IDDM patients (13 of 13) had BamHI fragments of 12 and 4 kb, detected in 9 of 17 controls (P < 0.02). The simple restriction fragment length polymorphism pattern of the IVS 1 probe was exploited by comparing 113 IDDM patients with 177 healthy controls to show increased prevalences in IDDM of the 12-kb (P < 0.0001) and 4-kb (P < 0.0001) frments. In IDDM patients younger than 20 yr at onset, 98% were 12-and/or 4-kb positive, compared with 63% of controls (P <0.0001), giving a relative risk of 91.8 for individuals with both fragments. The 12-kb fragment was linked to HLA-DR4, and the 4-kb fragment to HLA-DR3. Both serologic markers were split and a non-DR3/non-DR4 IDDM patient was 4-kb positive. HLA-DQ seems therefore closer, than HLA-DR, to an IDDM susceptibility gene.
Introduction
Type 1 (insulin-dependent) diabetes mellitus (IDDM)' affects primarily children and young adults and is the most common chronic metabolic disorder in childhood (see references 1-3 for reviews). The etiology is still unknown although virus or other environmental factors (1-4) have been implicated. The pathogenesis involves autoimmune phenomena, including the presence of insulitis (5, 6) , islet cell autoantibodies (reviewed in references 2 and 3), or other organ-specific autoimmune diseases (2, 7) . In contrast to the common view ofan acute and dramatic onset, IDDM seems to evolve after immune abnormalities are present but long before the clinical onset (8, 9) . The specific evanescence of the pancreatic # cells has yet to be clarified, but it is possible that certain autoantigens, such as an Mr 64,000 protein detected by IDDM sera (10) , direct the immune system 1 . Abbreviations used in this paper: IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus; RFLP, restriction fiagment length polymorphism. to the (3 cells. The disease seems to run in families, but the mode of inheritance has not been clarified. A familial hyperautoreactivity may be a prerequisite for IDDM to develop (1 1) , and the adverse autoimmune reaction against the pancreatic ft cells may be controlled by HLA genes in the major histocompatibility complex, inasmuch as > 90% of IDDM patients are HLA-DR3 and/or 4 positive (12, 13) .
Although these HLA-DR specificities account for nearly all IDDM patients, their frequencies in the background population amount to nearly 60% (12, 13) . The HLA-DR3/4 genotype is associated with the highest risk of developing IDDM. The concordance rate for IDDM among monozygotic twins remains, however, below 50% (14) and the risk of an HLA-DR-identical sibling developing IDDM is only 12%-24% (2, 13). HLA typing is therefore insufficient in predicting a development of IDDM also because recent epidemiologic data indicate that only 13% of new IDDM patients have an affected parent or sibling (15) . The question, therefore, remains whether there exist other genes linked to HLA-DR, which would confer a greater risk for IDDM to develop. The present study describes an approach by which to define disease susceptibility genes at the genomic level by the isolation of locus-specific genomic DNA probes derived from a polymorphic DNA fragment.
Recently, we (16, 17) and others (18, 19) described HLA-DQ-region 3-chain DNA endonuclease fragments that differ among HLA-DR-identical healthy and IDDM individuals. These observations are important, because they suggest that DNA polymorphism may define better the susceptibility to develop IDDM or other disorders found to be associated with HLA. The restriction fragment length polymorphisms (RFLP) detected by an HLA-DQ (3-chain complementary DNA (cDNA) probe are extensive and reveal complex endonuclease fragment patterns (16-24). Because we found that HLA-DR-identical control and IDDM individuals differ with respect to a BamHI 3.7-kb fragment detected with an HLA-DQ (3-chain cDNA probe (16, 17), we decided to clone this fragment from an HLA-DR4+ chromosome of a healthy individual (a) to establish its origin, (b) to determine the molecular basis of the RFLP, and (b) to test whether a fragment ofthe cloned BamHI 3.7-kb fragment could be used to obtain a less complex fragment pattern to increase the precision of RFLP analyses used for the detection of individuals that risk developing IDDM.
Gentofte, Denmark, 10-20 ml of blood, collected in the presence of heparin, was obtained at random from 113 patients, 38 (34%) females, 75 (66%) males, with ages varying between 2 and 66 yr at onset ofIDDM ( Fig. 1) , and also from 46 patients with non-insulin-dependent diabetes mellitus (NIDDM). The age distribution at the time ofadmittance (Fig.  1 ) was compatible with that previously reported for Denmark (25) . All the blood samples were obtained during routine visits, and were coded and analyzed in a random fashion. The fragments detected in the RFLP analysis were scored and recorded without the observer knowing the origin of the sample.
Cloning ofrestriction fragment. In our previous family study it was demonstrated that the RFLP observed after hybridization with an HLA-DQ E-chain probe was linked to HLA-DR (17) and that the BamHI 3.7-kb fragment appeared on three of six HLA-DR4-containing chromosomes in healthy individuals, but in 0 of 13 of the diabetic DR4-containing chromosomes (17). We selected one informative Swedish family without history of either IDDM or NIDDM to clone a BamHI 3.7-kb fragment from an HLA-DR4-containing chromosome (26) . The individual donating blood for cloning was a healthy HLA-DR2/4, 3.7-kb fragment-positive mother with two daughters. Her husband is HLA-DR3/7 and their two daughters are HLA-DR2/3 and 4/7, respectively. The HLA-DR4/7 daughter also has the BamHI 3.7-kb fragment, which is therefore present on the HLA-DR4-containing chromosome of the mother. Mononuclear cells were obtained from 30 ml ofblood by FicollHypaque gradient centrifugation and the DNA was extracted as described below. -50 ,g of DNA was digested with BamHI and electrophoresed in a 1% agarose gel along with appropriate molecular weight markers. The 3.4-3.8-kb region was sliced from the gel and the DNA fragments recovered by electroelution. This fraction of fragments was ligated into the BamHI site ofpUC8 and used to transform Escherichia coli JM 10528. Recombinant plasmids were recognized as those giving rise to white colonies on L-broth plates with 20 ,g/ml each of isopropyl thiogalactoside and 5-bromo-4-chloro-3-indolyl-,8-D-galactopyranoside, and were screened for HLA-DQ-related sequences by in situ hybridization on nitrocellulose filters with the nick-translated DQB8 cDNA probe (26 Vogt U/ml Si nuclease (Boehringer) to remove by incubation for 30 min at room temperature the single-stranded 3'-and Y-end protutions generated by Sphl and Exonuclease III, respectively. The reaction was terminated by phenol/chloroform extraction followed by ethanol precipitation. The pellets were resuspended in 10 1d 25 mM Tris-HC1 (pH 7.4) containing 5 mM MgC12, 5 mM dithiothreitol (DTT), 0.25 mM spermidine, I mM ATP, 10 Mg/ml BSA, and 700 U/ml T4 DNA ligase (Amersham) , and ligated at room temperature overnight. E. coli KM109 was transformed with 5 Ad of each of the ligated fractions according to Hanahan (30) and the bacterial cells spread on L-broth plates containing 50 Ag/ml ampicillin. About 10-20 transformants from each aliquot were selected for characterization of deletion size by agarose gel electrophoresis.
Each clone was grown overnight in a 5-ml L-broth culture in the presence of 50 Mg/ml ampicillin. Small-scale plasmid preparations were made by the alkaline lysis method (31) , with the following modifications. After precipitation with potassium acetate, supernatants were centrifuged for 2 min, transferred to fresh tubes containing 0.6 vol of isopropanol, and centrifuged for 5 min at 40C. The pellets were washed with 80% ethanol and resuspended in Tris-EDTA buffer. An equal volume of 4 M LiCl was added. After 5 min at 00C, the precipitates were collected by centrifugation for 2 min. The supernatants were incubated for 30 min at 371C with 25 Mg/ml RNase A, followed by phenol/chloroform extraction. The plasmid DNA was then precipitated by incubating the samples for 10 min at 00C in 2.5 vol of ethanol. After centrifugation, pellets were washed once each in 80% and 99% ethanol, air dried, and resuspended in Tris-EDTA buffer. The deletion breakpoints were estimated by agarose gel electrophoresis of appropriate restriction digest of the plasmid DNA. This analysis made it possible to decide which clones should be further characterized by sequencing.
Sequencing. Selected clones from the preparations described above were sequenced by the chain termination method, using double-stranded, supercoiled plasmid DNA (32) . Most clones from each aliquot had deletion breakpoints positioned within a range of 50-100 bp. The distance between fractions was roughly 100-200 bp.
Statistical evaluation. The difference in frequency between control and test samples was estimated by the Fisher exact test or the x2 test with Yate's correction. The level of significance was accepted to be P < 0.05 after the P value was corrected for the number of variable fragments observed between individuals. The relative risk (RR) was calculated from the formula. RR = (positive patients X negative controls)/(negative patients X positive controls), and the absolute relative risk (ARR) from ARR = (positive patients X total controls)/(positive controls X total patients) X prevalence of IDDM. The prevalence of IDDM in Denmark was 0.38% (25) .
Results
Sequence ofthe polymorphic BamHI TGG BCMTC6TAUTCCCCACT6CBGTM CCCACTCTTACCTGG6CCCTASTTCTGCGGAGCTACTTTG6ACGA6GAGTTCTAATTTCTTTAACCTAGGCCGCG  TTCCTGCCACCCCACTG6ACABTGGTTAMCT6CATM66TC6T666CTGTTM CATAMGTG666CATCACCTAATC6CACATCAGGCGTXACAAG TA6ACTTC   6TCAACAGCCTTA   TGTTTTATT   MACCCTTCACCTTCCCTCT CTATCCACTTGCTTMCTTC6T6AGTMCTCTTAT6C6M 6CCTCCTCMTCTTTTG  CCiTT6CtAA6CA6TCCTCTCT6CCCCCAAMCT6CCCTCTTCCCCT6CCC6Cr--CC6C C6CTA6CACTGCCCCACCCA6CAA66TCCAC6T6CACTC6TC6  CTCCACAM"GTCTGAGATTAACCTGTTGCTGTTAAAA CTACTCCACAACT6TGCMCATGTCATCCAGCAGTTACAMTT6TCATTAAMATATGMC ACTTT  TCACTTCAAATTATTATTCATCGTAATTCCATTTTCTTAMGT66CTCTCATTCATAACMATGCTCMSAGGT6ACTTTTGCTAGTCATCCCAT66CCCCTA  CCTCACTATTCACT6CASTGTA TATAACCTCATTAATCTTM TGTTAAATTAGTAGATAAAT6TSCTCAMCTGCCAATCCACTTA66CTATGTTTGTCA6   ATMTATCGCASTTGCCTTGCTACTTAAATTAGCATCATTtCATATATCCTTAATTAGTACASTAMACTCTTTTMTCACATCAAMTA  CTACAAA6TCACT CTCCMGGTCTCCACTATAMTGGACMTGAATACTTTCAAGCAGTTGAAATTAMCTTATTMTCTSCATTTAT6AT   CAT6AATTTTT CTTA PTTTC GT  TACATA6AATTTATTACATTATTCTATAAAATATTGTCACCTCTTTT66CCTA66TTCTCCCCTCCCCCC   ATCACTATCCACTT  CA TAACATTCTTAATSTTAATGGACCCATATAGTAGAC   AC   TtAMCTAAGTTCCCTTMGATGMACCATCTAT6TTATGTCA  MAATCTCSATATTTCCTCTA CATTAATGATTA6CATCACCACMATATATCCTMAATATTACTACAT6ATGAAACGM ATGAGTCAGCCCACAC6TACT  CACACCBACCTTGCCTGCG AAA6TACACAM TTAAAAGAATGAAAACACATCTCTAMAMGNXAASGCACAT6CCTAT6TTACCCASTTTTAC  CATM  M   MTCTCTTCCTAATTTGGCTCCAT6TTGATMG ACAATATACMCAGTTATMGG M ATTGTTCAT TCTTTATGAT  TATTCAATTTATGTTCCAATAGMATTCACMGACMCAGMACMATATCTTTCCATTCTGTTC ACTCACATCATACTAG66CAATACTT   ATATTM IAMCA6TTCTAMCCATAAAAM I I I   TTATCATCTTTTCTCATAAAM T6CCCTCTA I TTTITACTCCCAATCT6T6TAA6ATSAAC   AATCTTATAACCACATA6CT6AC'T6T6AMCA 66T66ACTCCA 6BUC-AAGAACMCA6TCTTMAAu6ATSACATCTT6TAA6T C CAATBT ATT6TCABOCSACTCCACTCA66USCC66TTCAA6TCAAC --AA6CA6 AC66TATCTCTTC66AT6AT66CTCATS AStmTW.A ATT6B66T CCACCT6CT6TCCTCA6CAATCCCA6CTATAT6TATATOTCSCATTACA66CTCATTAACCTA66CT6ACCTCT6CAA6T CTCA6AATATMTCTACA6^AG"CATACAT6ATAATATCT6ATTTTA66CAAAATAATTCTCAATA6CAA666AAT66A6TA666TA6ACA6CTA6TA DR4-containing chromosome showed the fragment, to which we refer as DQ13 3.7, to be 3,558 bp in length (Fig. 2) . Comparing this sequence (Table I) (Fig. 3) to differ from the cos 11-102 (33), whereas there were 11 amino acid substitutions compared with the other HLA-DR-associated DQ 1-chain sequence deduced from the KT3c2l cDNA clone (37) . It is noted that the amino acid substitutions in different HLA-DQ 13-chains primarily occur in positions 25-60 and 65-80 (Fig. 3) . In contrast, only two amino acid substitutions between DQ13 3.7 and cos II-102 were found in the second domain (Fig. 3) . It was concluded, therefore, that the BamHI 3.7-kb fiagment represents an HLA-DQ 1-chain gene, and that the two BamHI sites defining the fiagment were located in the first and third intervening sequences, respectively (Fig. 4) .
The IVS I probe detects differences between HLA-DR3/4 healthy and IDDM individuals. A probe was constructed from the cloned DQ# 3.7 fragment (Fig. 4) . This short (166-bp) IVS 1 probe was expected to hybridize only to closely related DQ/ DX-related 13-chain genes. Furthermore, because the IVS 1 probe primarily represents noncoding sequences, which may be less conserved than their coding counterparts, we assumed little crosshybridization to alleles ofdifferent genes and loci. We first tested 30 HLA-DR3/4' Danish individuals (Table II) , 13 ofthem were IDDM patients and 17 were healthy controls, to find a simple hybridization pattern (Fig. 5 ) of only five fragments being 12, 10, 4, and 3.7 and 3.2 kb (Table II) . The 10-kb fiagment was present among all individuals and all (13 of 13) IDDM patients had the 12-kb fiagment compared with 10 of 17 (59%) ofcontrols (P < 0.02). In fact, all IDDM patients were 12-and 4-kb positive although four different restriction enzyme patterns were found among the controls (Table II) .
Association between IDDM and the IVS 1 probe restriction fragments in a population study. The simplified restriction pattern and the likelihood that we were probing a limited number of DQ/DX-related 1-chain genes made it possible to test whether the IVS 1 probe would resolve differences between randomly selected IDDM patients and healthy individuals. Such a study would allow an analysis of the strength of a possible association between IDDM and the HLA-DQ locus. It was also important to establish whether the IVS 1 probe would reveal a simple hybridization pattern in the background population to permit studies on the relative risk of developing diabetes without previous knowledge of HLA types. Therefore, we compared 177 healthy, adult blood donors (controls) with 1 100  110  120  130  140  150  160  170  180 
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(DR3 .6) ---------------------I--------S--------------A-----------------------T--R--------------S------Figure 3 . Comparison between the deduced amino acid sequence of the DQ 3.7 fragment with published HLA-DQ 13-chain sequences. See Table I for reference to previously published sequences. The presence of distinct hybridization signals were seen in all individuals (Fig. 5) to yield a single nonpolymorphic fragment of 10 kb and only six variable fragments. Among the 1 3 IDDM patients and including the 10-kb fragment, 25 (21%), 76 (65%) (P < 0.001), and 16 (14%) (P < 0.001) had two, three, or four restriction fragments, respectively, compared with 25 (14%), 79 (45%), and 71 (40%) among the controls. Only two controls had as many as five and six fragments, respectively. Analysis of the frequency of individual fragments among IDDM patients and controls revealed additional differences (Table III) . Correcting the P values for the number of variable fragments observed, it was demonstrated that the 12-kb (P < l0-4) and 4-kb (P < l0-4) fragments were increased among the IDDM patients whereas the 7.5-kb (P < l0-4) and 3.7 kb (P < 10-3) fragments were decreased. As many as 108 of 113 (92%) of the IDDM patients had the 12-and/or the 4-kb fragment compared with 112 of 177 (63%) of the controls (P < l0-4) ( Table IV) . The simultaneous presence of the 12-and 4-kb fragments was found among 40 of 113 (34%) IDDM compared with 17 of 177 (10%) control individuals (P < l0-4). There were no differences between sex in the frequency distribution of the different fragments.
HLA -DQ gene
We analyzed the frequency of the different fragments in relation to age at onset (Fig. 1, Table IV ). Among the 43 IDDM patients with age at onset below 20 yr, 42 (98%) were 12-and/ or 4-kb positive compared with 1 12 of 177 (63%) ofthe controls (P < 10-4). The 12-4-kb-positive individuals amounted to 24 (56%), found only among 17 of 177 (10%) controls (P < 10-4).
The relative risk for a young 12-4-kb-positive individual to develop IDDM amounts, therefore, to 91.8 compared with the control individuals who are negative for both ofthese fragments. The absolute relative risk was 2.2%.
The presence or absence of the 12-kb and/or 4-kb fragments were also analyzed in a group of46 patients with NIDDM (Table   IV) The IVS 1 probe seems to be specific for the HLA-DQ/DX locus because we found only one to three variable fragments per individual. The nonpolymorphic 10-kb fragment presumably represents the HLA-DX 3-chain gene, We note that the 7.5-, 3.0-, and the 2.8-kb fragments never occur alone, and that the 3.0-kb always appears together with the 7.5-kb fragment. Some of these fragments may therefore occur in the same haplotype.
The high relative risk value of 91.8 for the simultaneous presence of the 12-and 4-kb fragments (Table IV) may be due to the ability of the IVS 1 probe to differentiate between subtypes of both HLA-DR4 and DR3. Because the 166-bp IVS sequence was most closely related to previously described DQ ,8-chain gene sequences (27, (33) (34) (35) (36) (37) , we argue that, the DQ ,3-chain gene either represents a diabetes-susceptibility gene or is closer to a putative susceptibility gene than the HLA-DR locus. This would be particularly true for individuals developing IDDM below the age of 20 yr (Table IV) . This conclusion is supported by the recent observation that the HLA-DQ-specific monoclonal antibody, TA 10 (42), differentiates between HLA-DR4 identical IDDM and control individuals (Tait, personal communication).
We compared the intervening sequences of our BamHI 3.7-kb fragment with the two published DQ intervening sequences which are associated with HLA-DR4 (cos II-102) (33) and HLA-DR3 (DC3(3) (34), respectively. Because the DC3(3 was cloned from a DR3/3 homozygous cell line, we would predict the presence of a BamHI fragment of -4 kb rather than 3.6 kb. However, both BamHI restriction sites in the IVS 1 and IVS 3 ( Fig.   2) were preserved in the DC3(3 sequence (34) . Therefore, when analyzing the IVS 2 sequence of cos II-102 with that of DC3(3 we found that the latter was 300 bp larger, because ofthe insertion of an Alu sequence which was not reported by the authors (34) .
It is important to note that the DQ 3.7-kb fragment had no sequences corresponding to the Alu sequence of the DC3(3. Furthermore, plasmid DNA, containing the DQ 3.7 fragment, did not hybridize with the Alu-sequence probe BLUR 2 (44) (data not shown). Therefore, RFLP associated to the development of IDDM, or other diseases associated to HLA, may be linked not only to the absence or presence of certain restriction enzyme sites but to insertion of sequences as well.
The two BamHI restriction sites in the IVS 1 and IVS 3 of the DQ 3.7-kb fragment (Fig. 1) are missing in the cos 11-102 (33) . The restriction enzyme map of this cosmid clone suggests that the IVS 1 probe sequence is contained within a BamHI fragment that is larger than 6 kb. Because cos II-102 is from an HLA-DR4' individual, its DQ (-chain gene may contain a BamHI 12-kb fragment. The BamHI 3.7-kb polymorphism would therefore be caused by either point mutations or the presence of unknown inserted sequences within noncoding regions. However, even though these events have occurred in noncoding sequences, it is notable that all three alleles of the HLA-DQ (3- chain gene also differ in their coding regions (Fig. 3) .
Our further studies involve cloning and sequencing of the 12-and 4-kb fragments from IDDM patients. This is important, because these two approaches will not only give further structural information on the HLA-DQ ,8-chain genes but also allow us to derive yet other probes from IDDM patients and permit further dissection ofdisease susceptibility, both in population and family studies. Sequence information should also resolve whether the 12-kb fragment on HLA-DR4-containing chromosomes is related to the HLA-DR2-associated BamHI 12-kb fragment found to be positively associated with multiple sclerosis (18) .
Our approach in cloning RFLP fragments should eventually lead to the identification of an HLA-D locus gene that gives maximal susceptibility to develop IDDM. It has been previously shown that HLA-DR3 and 4 have different regulatory functions on the proliferative T lymphocyte response to mumps and coxsackie B4 (45) , two viruses implicated in the etiology of IDDM (4). Class II antigens confer restriction in antigen presentation perhaps by direct binding of processed antigen (46) . Isolation and structural analysis of these HLA-D class II molecules will therefore be of central importance in testing the hypothesis (2, 47, 48 ) that the pathogenesis of IDDM is conferred by the ability of these molecules to present antigens that induce an abnormal immune response against the pancreatic (3cells.
